Clinical trials: sponsored by Florida State University
PTSD, Post Traumatic Stress Disorder
Feasibility of a Digital Therapeutic for Adults With Posttraumatic Stress Disorder (PTSD)
This study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.
- Trial name
- NCT06868446
- Testing
- OTX-601 Digital Therapeutic - Version 1, OTX-601 Digital Therapeutic - Version 2, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Oui Therapeutics, Inc.
PTSD, Post Traumatic Stress Disorder
Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms
This study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.
- Trial name
- NCT07316088
- Testing
- OTX-601 Digital Therapeutic, OTX-003 Comparator app
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Oui Therapeutics, Inc.
Ovarian Cancer, Breast Cancer
Comprehensive Outcomes for After Cancer Health
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
- Trial name
- COACH (NCT05349227)
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 7 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pack Health
Sepsis
Changes in Exhaled 13CO2/12CO2 Breath Delta Value as an Early Indicator of Infection in ICU Patients
Carbon-12 and carbon-13 are naturally-abundant isotopes in exhaled breath carbon dioxide. The ratio of carbon-13 to carbon-12 in exhaled breath is known as the breath delta value (BDV).
- Trial name
- NCT02327130
- Testing
- Isomark Canary™
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Isomark, LLC
Breast Cancer
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients.
- Trial name
- MINT (NCT01501487)
- Testing
- TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy
- Where
- 9 sites in United States
- Volunteers
- 226 people
- Sponsor
- Agendia
Lung Cancer
Airway Epithelium Gene Expression: AEGIS IDE
The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured.
- Trial name
- AEGIS IDE (NCT00746759)
- Testing
- Biomarker (not used as an intervention)
- Where
- 21 sites in United States
- Volunteers
- 1,331 people
- Sponsor
- Allegro Diagnostics, Corp.